Rankiteo Logo
Rankiteo
Leader in Cyber Underwriting
Loading...
NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop
WindowsmacOSLinux
Download

Comparison Overview

Lek, a Sandoz companyLek, a Sandoz company
VS
Johnson & Johnson Innovative MedicineJohnson & Johnson Innovative Medicine
Lek, a Sandoz company

Lek, a Sandoz company

Verovškova 57, Ljubljana, 1526, SI

Last Update: 21/04/2026

View Profile
Between 750 and 799
http://www.lek.si
759/1000Fair

Lek, a Sandoz company, is the first and oldest pharmaceutical company in Slovenia, with 80 years of tradition. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We develop, manufacture and market e...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:1,510
Subsidiaries:24
12-month incidents
0
Known data breaches
0
Attack type number
0
Johnson & Johnson Innovative Medicine

Johnson & Johnson Innovative Medicine

N/A

Last Update: 31/03/2026

View Profile
807/1000Good

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with co...

NAICS:3254
NAICS Definition:Pharmaceutical and Medicine Manufacturing
Employees:37,729
Subsidiaries:10
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Ranges Comparison

Based On Specific Ai Models Category
Lek, a Sandoz company

Lek, a Sandoz company

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA
Johnson & Johnson Innovative Medicine

Johnson & Johnson Innovative Medicine

-
ISO 27001Not verified
ISO 27001
-
SOC2 Type 1Not verified
SOC2 Type 1
-
SOC2 Type 2Not verified
SOC2 Type 2
-
GDPRNot verified
GDPR
-
PCI DSSNot verified
PCI DSS
-
HIPAANot verified
HIPAA

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Lek, a Sandoz company in 2026.

Incidents

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Johnson & Johnson Innovative Medicine in 2026.

Incidents

Incident History - Lek, a Sandoz company (X = Date, Y = Severity)

Lek, a Sandoz company cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Incident History - Johnson & Johnson Innovative Medicine (X = Date, Y = Severity)

Johnson & Johnson Innovative Medicine cyber incidents detection timeline including parent company and subsidiaries.

No timeline data available
R - Ransomware
C - Cyber Attack
D - Data Breach
V - Vulnerability

Notable Incidents

Last Cyber / HR Incidents / Global...
Lek, a Sandoz company

Lek, a Sandoz company

Incidents
No explicit notable incidents reported.
Johnson & Johnson Innovative Medicine

Johnson & Johnson Innovative Medicine

Incidents
No explicit notable incidents reported.

FAQ

Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one has the best AI Cybersecurity Score ?
Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one has experienced more cyber incidents in the past ?
Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one has experienced more cyber incidents this year ?
Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one has experienced at least one ransomware attack ?
Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one has experienced at least one data breach ?
Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one has experienced at least one targeted cyberattack ?
Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one has experienced at least one vulnerability ?
Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one holds the most compliance certifications ?
Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one holds the fewest compliance certifications ?
Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one has the most subsidiaries ?
Between Lek, a Sandoz company company and Johnson & Johnson Innovative Medicine company, which one has the largest number of employees ?
Between Lek, a Sandoz company and Johnson & Johnson Innovative Medicine, which company holds both SOC 2 Type 1 certifications ?
Between Lek, a Sandoz company and Johnson & Johnson Innovative Medicine, which company holds both SOC 2 Type 2 certifications ?
Which company is ISO 27001 certified - Lek, a Sandoz company or Johnson & Johnson Innovative Medicine ?
Which company is PCI DSS compliant - Lek, a Sandoz company or Johnson & Johnson Innovative Medicine ?
Between Lek, a Sandoz company and Johnson & Johnson Innovative Medicine, which company complies with HIPAA regulations for healthcare data ?
Between Lek, a Sandoz company and Johnson & Johnson Innovative Medicine, which company complies with GDPR requirements ?

Latest Global CVEs

CVE-2026-58523
SUMMARY

Improper access control in Microsoft Edge for Android allows an unauthorized attacker to bypass a security feature over a network.

PUBLISHED
Date2026-07-03
UPDATED
Date2026-07-03
RISK INFORMATION (Score: 6.5)
CVSS3
Base Score: 6.5
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:H/I:N/A:N
IMPACT SCORE
3.6
EXPLOITABILITY
2.8
CVE-2026-14617
SUMMARY

A security vulnerability has been detected in NousResearch hermes-agent up to 2026.4.30. Affected is the function GatewayStreamConsumer._filter_and_accumulate of the file gateway/stream_consumer.py of the component Streaming Reasoning Tag Filter. The manipulation leads to improper handling of case sensitivity. The attack may be initiated remotely. The attack's complexity is rated as high. The exploitability is told to be difficult. The exploit has been disclosed publicly and may be used. The project decided to not implement a dedicated fix: "[T]he analysis and the fix are both sound. It just lands below the bar for the maintenance cost of a duplicated scrub path."

PUBLISHED
Date2026-07-03
UPDATED
Date2026-07-03
RISK INFORMATION (Score: 3.1)
CVSS2
Base Score: 2.1
Complexity: HIGH
AV:N/AC:H/Au:S/C:P/I:N/A:N
CVSS3
Base Score: 3.1
Complexity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N
CVSS4
Base Score: 1.3
Complexity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
IMPACT SCORE
1.4
EXPLOITABILITY
1.6
CVE-2026-58597
SUMMARY

Insufficient ui warning of dangerous operations in Microsoft Edge (Chromium-based) allows an unauthorized attacker to perform spoofing over a network.

PUBLISHED
Date2026-07-03
UPDATED
Date2026-07-03
RISK INFORMATION (Score: 4.3)
CVSS3
Base Score: 4.3
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:N/A:N
IMPACT SCORE
1.4
EXPLOITABILITY
2.8
CVE-2026-58524
SUMMARY

Improper neutralization of input during web page generation ('cross-site scripting') in Microsoft Edge (Chromium-based) allows an unauthorized attacker to perform spoofing over a network.

PUBLISHED
Date2026-07-03
UPDATED
Date2026-07-03
RISK INFORMATION (Score: 5.4)
CVSS3
Base Score: 5.4
Complexity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N
IMPACT SCORE
2.5
EXPLOITABILITY
2.8
CVE-2026-58522
SUMMARY

Relative path traversal in Microsoft Edge for Android allows an unauthorized attacker to disclose information locally.

PUBLISHED
Date2026-07-03
UPDATED
Date2026-07-03
RISK INFORMATION (Score: 6.8)
CVSS3
Base Score: 6.8
Complexity: LOW
CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:H/I:L/A:N
IMPACT SCORE
4.2
EXPLOITABILITY
2.5